WO2016100452A3 - Composés hétéroaryle et utilisations associées - Google Patents

Composés hétéroaryle et utilisations associées Download PDF

Info

Publication number
WO2016100452A3
WO2016100452A3 PCT/US2015/066002 US2015066002W WO2016100452A3 WO 2016100452 A3 WO2016100452 A3 WO 2016100452A3 US 2015066002 W US2015066002 W US 2015066002W WO 2016100452 A3 WO2016100452 A3 WO 2016100452A3
Authority
WO
WIPO (PCT)
Prior art keywords
heteroaryl compounds
erki
same
present
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/066002
Other languages
English (en)
Other versions
WO2016100452A2 (fr
Inventor
Lixin Qiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Avilomics Research Inc
Original Assignee
Celgene Avilomics Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Avilomics Research Inc filed Critical Celgene Avilomics Research Inc
Publication of WO2016100452A2 publication Critical patent/WO2016100452A2/fr
Publication of WO2016100452A3 publication Critical patent/WO2016100452A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés qui inhibent l'activité de la protéine kinase ERK1 et/ou de la protéine kinase ERK2, des compositions pharmaceutiquement acceptables de ceux-ci, et des procédés d'utilisation de ceux-ci.
PCT/US2015/066002 2014-12-17 2015-12-16 Composés hétéroaryle et utilisations associées Ceased WO2016100452A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093037P 2014-12-17 2014-12-17
US62/093,037 2014-12-17

Publications (2)

Publication Number Publication Date
WO2016100452A2 WO2016100452A2 (fr) 2016-06-23
WO2016100452A3 true WO2016100452A3 (fr) 2016-07-28

Family

ID=56127841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/066002 Ceased WO2016100452A2 (fr) 2014-12-17 2015-12-16 Composés hétéroaryle et utilisations associées

Country Status (1)

Country Link
WO (1) WO2016100452A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120028923A1 (en) * 2010-07-28 2012-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8440822B2 (en) * 2007-04-18 2013-05-14 Michael Joseph Luzzio Sulfonyl amide derivatives for the treatment of abnormal cell growth
US20130158032A1 (en) * 2011-11-29 2013-06-20 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
US8735400B2 (en) * 2009-01-23 2014-05-27 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20140228322A1 (en) * 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440822B2 (en) * 2007-04-18 2013-05-14 Michael Joseph Luzzio Sulfonyl amide derivatives for the treatment of abnormal cell growth
US8735400B2 (en) * 2009-01-23 2014-05-27 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20120028923A1 (en) * 2010-07-28 2012-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20130158032A1 (en) * 2011-11-29 2013-06-20 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
US20140228322A1 (en) * 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2016100452A2 (fr) 2016-06-23

Similar Documents

Publication Publication Date Title
ZA201906822B (en) Indole ahr inhibitors and uses thereof
WO2018006074A3 (fr) Composés et méthodes permettant de moduler la fonction de l'arn
EP4501932A3 (fr) Inhibiteurs de kras g12c
CA3010752A1 (fr) Inhibiteurs de l'interaction proteine/proteine pd-1/pd-l1
WO2016044463A3 (fr) Inhibiteurs de mk2 et leurs utilisations
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
EP3672973A4 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinase, compositions comprenant le composé hétérocyclique, et leurs procédés d'utilisation
WO2017050791A8 (fr) Nouveaux composés bicycliques utilisés en tant qu'inhibiteurs doubles d'atx/ca
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
EP4327809A3 (fr) Inhibiteurs de tyk2 et leurs utilisations
WO2017136450A3 (fr) Composés et méthodes de traitement de maladies médiées par l'arn
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
WO2014011911A3 (fr) Inhibiteurs d'irak et leurs utilisations
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
WO2015200680A8 (fr) Inhibiteurs de prmt5 et leurs utilisations
EP4234552A3 (fr) Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations
WO2014011906A3 (fr) Inhibiteurs d'irak et leurs utilisations
WO2012021444A8 (fr) Sel de bésylate d'un inhibiteur de btk
WO2015120062A3 (fr) Composés et compositions thérapeutiques
EP4112611A3 (fr) Modulateurs d'interaction sestrine-gator2 et leurs utilisations
IN2014DN10576A (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15870951

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15870951

Country of ref document: EP

Kind code of ref document: A2